Evolus Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Evolus wird ein jährliches Gewinn- und Umsatzwachstum von 69.1% bzw. 23.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 69.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -283% betragen.

Wichtige Informationen

69.1%

Wachstumsrate der Gewinne

69.1%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.6%
Wachstumsrate der Einnahmen	23.4%
Zukünftige Eigenkapitalrendite	-283.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	02 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10

Recent updates

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Evolus: Turning That Frown Upside Down

Sep 11

Evolus appoints Experian's exec as CFO

Aug 30

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Aug 04

Evolus Q2 2022 Earnings Preview

Aug 01

Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Mar 21

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:EOLS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	461	44	98	126	7
12/31/2025	351	-14	17	27	7
12/31/2024	267	-43	-15	9	6
6/30/2024	237	-53	-20	-17	N/A
3/31/2024	220	-60	-26	-24	N/A
12/31/2023	202	-62	-36	-34	N/A
9/30/2023	185	-63	-46	-44	N/A
6/30/2023	169	-66	-63	-60	N/A
3/31/2023	156	-72	-70	-67	N/A
12/31/2022	149	-74	-88	-85	N/A
9/30/2022	140	-79	-87	-85	N/A
6/30/2022	132	-79	-101	-100	N/A
3/31/2022	121	-71	-64	-63	N/A
12/31/2021	100	-47	-34	-33	N/A
9/30/2021	86	-139	-27	-27	N/A
6/30/2021	77	-131	-10	-8	N/A
3/31/2021	58	-137	-40	-38	N/A
12/31/2020	57	-163	-61	-58	N/A
9/30/2020	55	-67	-76	-72	N/A
6/30/2020	51	-82	-87	-83	N/A
3/31/2020	45	-99	-107	-102	N/A
12/31/2019	35	-90	-98	-93	N/A
9/30/2019	15	-88	-93	-89	N/A
6/30/2019	2	-73	-73	-70	N/A
3/31/2019	N/A	-52	-43	-43	N/A
12/31/2018	N/A	-47	-26	-26	N/A
9/30/2018	N/A	-30	-15	-15	N/A
6/30/2018	N/A	-21	-12	-12	N/A
3/31/2018	N/A	-7	N/A	-10	N/A
12/31/2017	N/A	-4	N/A	-13	N/A
9/30/2017	N/A	-13	N/A	-14	N/A
6/30/2017	N/A	-14	N/A	-13	N/A
3/31/2017	N/A	-18	N/A	-14	N/A
12/31/2016	N/A	-20	N/A	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EOLS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.5%).

Ertrag vs. Markt: EOLS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: EOLS wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: EOLSDie Einnahmen des Unternehmens (23.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: EOLSDie Einnahmen des Unternehmens (23.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: EOLS wird voraussichtlich in 3 Jahren unrentabel sein.

Evolus Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Evolus, Inc. Raises Financial Guidance for the Full Year of 2024

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Forecast breakeven date moved forward to 2025

Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Price target increased by 7.6% to US$22.29

Recent updates

Evolus Continues To Make Progress

Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Evolus, Inc. Raises Financial Guidance for the Full Year of 2024

Evolus, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Evolus: Chiseling Away At The Aesthetic Market

President recently sold US$204k worth of stock

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024

Evolus, Inc. to Report Q1, 2024 Results on May 07, 2024

Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau

Evolus, Inc. Announces Board Changes

President recently sold US$1.3m worth of stock

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million.

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Price target increased by 7.6% to US$22.29

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Independent Director notifies of intention to sell stock

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Evolus, Inc. Announces Earnings Guidance for 2024

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

New minor risk - Shareholder dilution

President recently sold US$822k worth of stock

President notifies of intention to sell stock

New minor risk - Insider selling

No longer forecast to breakeven

Evolus, Inc. Raises Earnings Guidance for the Full Year 2023

Price target increased by 12% to US$20.25

Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau

Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

President recently sold US$152k worth of stock

Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Evolus, Inc. Revises Revenue Guidance for the Year 2023

Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy

Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R)

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Price target increased by 9.4% to US$18.11

Consensus EPS estimates fall by 46%

Price target increased by 8.4% to US$17.22

Evolus, Inc. Provides Revenue Guidance for the Year 2023

Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings: EPS misses analyst expectations

Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance

Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia

Evolus, Inc. Provides Earnings Guidance for the Year 2023

Forecast to breakeven in 2025

Insufficient new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Evolus, Inc. Provides Earnings Guidance for the Full Year 2022

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Evolus: Turning That Frown Upside Down

Independent Director recently bought US$91k worth of stock

Evolus, Inc. Names Sandra Beaver as Its Chief Financial Officer, Effective September 5, 2022

Evolus appoints Experian's exec as CFO

Consensus forecasts updated